Filtered By:
Condition: Headache
Nutrition: Vitamin A

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 19 results found since Jan 2013.

Rational clinical approach to transient ischaemic attack, stroke and associated mimics: A retrospective cohort study
CONCLUSIONS: The present study demonstrated that specific clinical features and risk factors were associated with the final diagnosis at TIA clinic. These clinical features may assist with diagnosis of TIA in centres without access to a vascular neurologist.PMID:37190670 | DOI:10.1111/1742-6723.14238
Source: Atherosclerosis - May 16, 2023 Category: Cardiology Authors: Rudy Goh Stephen Bacchi Lydia Lam Timothy Kleinig Jim Jannes Source Type: research

Ischemic stroke is a potential complication of uncontrolled inflammation in mevalonate kinase deficiency – A case report
Mevalonate kinase deficiency (MKD) is an autosomal recessive monogenic autoinflammatory disease (AID) characterized by recurrent antigen-independent systemic inflammation attacks, interleukin-1beta hypersecretion, fever and pain.1 Neurological manifestations include headaches, fatigue, retinal dystrophy, ataxia and development delay.2
Source: Journal of Stroke and Cerebrovascular Diseases - October 12, 2022 Category: Neurology Authors: Justine Blais, Didier Bonneville-Roussy, Hannah Laure Elfassy, Sylvain Lanthier Tags: Case Report Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mitochondrial Disorder: Maternally Inherited Diabetes and Deafness.
Authors: Tsang SH, Aycinena ARP, Sharma T Abstract Patients with maternally inherited diabetes and deafness (MIDD) have insulin-dependent diabetes with relatively low BMI; usually the onset of the diabetes is during the third or fourth decade of life and it is associated with progressive neurosensory deafness. The fundus shows circumferentially oriented but discontinuous patches of RPE and choriocapillaris (CC) atrophy around the macula, within the arcades (Figs. 31.1 and 31.2). Sometimes even hyperpigmentation can be seen, also around the optic nerve, or pattern-like dystrophy may occur. Vision is usually good, ab...
Source: Advances in Experimental Medicine and Biology - December 25, 2018 Category: Research Tags: Adv Exp Med Biol Source Type: research

What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Carotid ergotism with retinal ischemia
Ergot poisoning was first described more than 2,000 years ago with the consumption of food contaminated with mycotoxins. It acquired special importance during the 20th century because of an excessive consumption of ergot pharmaceuticals as symptomatic treatment of migraine.1,2
Source: Neurology Clinical Practice - April 9, 2018 Category: Neurology Authors: Altuna-Azkargorta, M., Herrera-Isasi, M., Zandio-Amorena, B., Bacaicoa-Saralegui, M. C. Tags: Migraine, All Clinical Neurology, All Cerebrovascular disease/Stroke, Critical care Case Source Type: research

Electroconvulsive therapy: 80 years of use in psychiatry.
Authors: Kaliora SC, Zervas IM, Papadimitriou GN Abstract Electroconvulsive therapy (ECT) is the oldest among the early biological treatments introduced in psychiatry, and the only one still in use. In this paper we attempt a brief presentation of ECT usage over the last 80 years, since it was originally introduced. It is a safe, well-tolerated, and highly effective treatment option for major psychiatric disorders, such as mood disorders and schizophrenia, especially when there is an acute exacerbation of psychotic symptoms or if catatonic symptoms are prominent. ECT has also been used successfully for the treatmen...
Source: Psychiatriki - March 4, 2019 Category: Psychiatry Tags: Psychiatriki Source Type: research

Intrathecal baclofen as emergency treatment alleviates severe intractable autonomic dysreflexia in cervical spinal cord injury.
Conclusion/Clinical Relevance: The case demonstrated that refractory AD could be managed with ITB in an emergency. PMID: 31815605 [PubMed - as supplied by publisher]
Source: Journal of Spinal Cord Medicine - December 10, 2019 Category: Orthopaedics Tags: J Spinal Cord Med Source Type: research

Migraine Aura: Updates in Pathophysiology and Management
AbstractPurpose of ReviewTo provide an updated review of the pathophysiology, diagnosis, and management of migraine with aura.Recent FindingsThalamic and other subcortical regions may play a role in the pathophysiology of migraine. There is inter-patient and intra-patient attack variability in the characteristics of typical aura especially visual aura symptoms. Migraine with brainstem aura may originate cortically. Migraine with retinal aura may be associated with structural and functional changes in the retina.SummaryAlthough cortical spreading depression (CSD) continues to be the predominant theory surrounding the pathop...
Source: Current Neurology and Neuroscience Reports - May 18, 2020 Category: Neuroscience Source Type: research

Migraine Aura: Updates in Pathophysiology and Management.
Abstract PURPOSE OF REVIEW: To provide an updated review of the pathophysiology, diagnosis, and management of migraine with aura. RECENT FINDINGS: Thalamic and other subcortical regions may play a role in the pathophysiology of migraine. There is inter-patient and intra-patient attack variability in the characteristics of typical aura especially visual aura symptoms. Migraine with brainstem aura may originate cortically. Migraine with retinal aura may be associated with structural and functional changes in the retina. Although cortical spreading depression (CSD) continues to be the predominant theory surround...
Source: Epilepsy Curr - May 18, 2020 Category: Neurology Authors: Lai J, Dilli E Tags: Curr Neurol Neurosci Rep Source Type: research